Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

bluebird bio : to Present at Jefferies Cell Therapy Virtual Summit

share with twitter share with LinkedIn share with facebook
09/28/2020 | 09:03am EDT

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET.

To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders, including cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using three gene therapy technologies: gene addition; cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash., Durham, N.C., and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about BLUEBIRD BIO, INC.
10/02BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/02BLUEBIRD BIO : Announces European Medicines Agency's Acceptance of Marketing Aut..
BU
10/01BLUEBIRD BIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/28BLUEBIRD BIO : Corporate Presentation - September 2020
PU
09/28BLUEBIRD BIO : to Present at Jefferies Cell Therapy Virtual Summit
BU
09/23BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/23BLUEBIRD BIO : LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) ..
BU
09/22BLUEBIRD BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/22Bristol Myers, Bluebird Get FDA Priority Review for Ide-cel
DJ
09/02BLUEBIRD BIO : Announces September Investor Events
BU
More news
Financials (USD)
Sales 2020 270 M - -
Net income 2020 -620 M - -
Net cash 2020 1 163 M - -
P/E ratio 2020 -5,46x
Yield 2020 -
Capitalization 3 677 M 3 677 M -
EV / Sales 2020 9,30x
EV / Sales 2021 17,8x
Nbr of Employees 1 167
Free-Float 99,5%
Chart BLUEBIRD BIO, INC.
Duration : Period :
bluebird bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLUEBIRD BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 104,94 $
Last Close Price 55,53 $
Spread / Highest target 253%
Spread / Average Target 89,0%
Spread / Lowest Target 22,5%
EPS Revisions
Managers
NameTitle
Nick Leschly President, Chief Executive Officer & Director
Daniel S. Lynch Chairman
Jason F. Cole Chief Operating & Legal Officer
William Denise Baird Chief Financial Officer
David M. Davidson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEBIRD BIO, INC.-36.72%3 677
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097